Press Room

Tools and Resources for Media Professionals.

Multimedia Assets

Need a FULL press kit?

Download here.

Latest Press Release

 

Former Inogen CEO, Ray Huggenberger, Joins Ebb Therapeutics Board of Directors

 

PITTSBURGH, September 18, 2018 /PRNewswire/ — Ebb Therapeutics, a med-tech start-up that develops innovative products designed to help the millions of insomnia sufferers, announces that its added Ray Huggenberger to its Board of Directors.

During Huggenberger’s nine-year tenure as the CEO of Inogen (INGN), the medical technology company that develops, manufactures and markets oxygen concentrators, it experienced extraordinary growth and cemented its category leadership position, further distancing itself from any potential competitors. Mr. Huggenberger will remain on Inogen’s Board of Directors.

“Ray is the perfect executive to fill our last Board seat. His experience in successfully launching new-to-category medical technologies, via direct-to-consumer marketing, is analogous to our current business model. And his strategic insights for building the business, first in the United States, and then globally, will be invaluable,” said CEO,
Ebb Therapeutics Inc., Don Spence.

Prior to joining Inogen, Huggenberger held various executive leadership roles with companies including Sunrise Medical Inc., a global manufacturer of durable medical equipment, and the healthcare division of TA Triumph Adler.

Mr. Huggenberger also serves on the Board of Wellfount Corporation, a pharmacy services company, as well as Clarify Medical, a dermatology company, Sommetrics, a respiratory company and Tactile Medical (TCMD), a publicly-traded medical device company for the treatment of lymphedema.

“Insomnia and general sleeplessness have reached global crisis status, with 174+ million sufferers in America alone. And until now, the market hasn’t seen a fully credible, clinically-validated and completely drug-free alternative to sleeping pills. Ebb Insomnia Therapy is a category-disrupting product, backed by ten years of evidential data that has allowed it to secure FDA clearance. I’m excited to partner with the company’s executive leadership team in what will prove to be a successful, commercialization journey,” said Huggenberger.

About Ebb Therapeutics

Headquartered in Pittsburgh, PA, the privately-held company was founded in 2008 by Eric Nofzinger, M.D., after he performed pioneering brain imaging studies on insomnia patients at the University of Pittsburgh. His research resulted in the development of Ebb Insomnia Therapy, a clinically-safe, medical-grade device, with none of the side effects found in traditional treatments. Ebb Therapeutics was funded in part by a grant from the National Institutes of Health, as well as private equity and venture capital firms, KKR, Arboretum Ventures, Versant Ventures and Partner Ventures.

To learn more, visit http://www.ebbsleep.com.

Inquiries:

Elise Wilfinger
Chief Marketing Officer
Ebb Therapeutics
ewilfinger@ebbsleep.com

 



 

 

Ebb Therapeutics in the News

Cerêve Raises $38 Million to Fuel Launch of Insomnia Device in New Financing Led by KKR

Investment Will Fund Launch of FDA-cleared Device to Safely Treat Insomnia

OAKMONT, Pa.–(BUSINESS WIRE)–Jan. 5, 2017– Cerêve Inc., a privately-held health care company preparing to launch its FDA-cleared insomnia device, announced today the closing of a $38 million Series B round of financing led by KKR, a leading global investment firm. Also participating in the financing are existing shareholders Versant Ventures, Arboretum Ventures, and Partner Ventures.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005480/en/

Fifty-five million Americans have insomnia, not only experiencing problems getting to sleep but also serious impairment in their daytime activities. Currently, sleeping pills are the most common medical treatment for insomnia. According to the National Center for Health Statistics…


FDA Clears Sleep Device for Insomnia – System cools hyperactive frontal cortex

The FDA has granted commercial clearance for the Cerêve Sleep System, a prescription device that reduces latency to stage-1 and stage-2 sleep for people with insomnia.

Functional brain-imaging studies have shown that the frontal cortex, or executive brain, remains active in people with insomnia during sleep, preventing them from getting deeper, more-restorative sleep. The Cerêve Sleep System consists of a software-controlled bedside device that cools and pumps fluid to a forehead pad that is worn through the night. The pad cools the forehead within a clinically proven therapeutic range to reduce hyperactivity in the frontal cortex…


Ebb sleep in Pittsburgh Business TimesPitt spinoff on insomnia: Cooler heads do prevail

Studies at the University of Pittsburgh found that the brains of patients with insomnia were overactive. Pitt had a patent for a technique to reduce brain metabolic activity using cooling, and Dr. Eric Nofzinger saw the potential.

The burgeoning business of sleep is awakening.

Nationally, the global sleep services market is expected to reach $8.4 billion by the end of 2021, according to Persistence Market Research. And as more people are seeking new ways to bolster the quality of their shut-eye, local companies are developing products to address everything from insomnia and sleep apnea to keeping special needs kids from getting injured at night. Here are their stories…


Need a Helping Hand?

 

We’re delighted to offer our expertise in any sleep related project.
We work tirelessly every day, to help people sleep a little easier every night.

Press Contact

Elaine Lesnak

Director of Marketing Communications

412-517-6731

elesnak@ebbsleep.com

Connect with Ebb

Request a Phone Call

Have an Ebb Customer Care Coordinator contact you to discuss your next steps in getting the sleep you deserve.

* indicates required

We take your privacy extremely seriously, and we never sell lists or email addresses.View our privacy policy.